SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Global Diabetic Therapeutic Market 2017-2021: The Strong Potential of Biologics - Leading Players are AstraZeneca, Eli Lilly, Merck, Novo Nordisk & Sanofi - Research and Markets
[April 19, 2017]

Global Diabetic Therapeutic Market 2017-2021: The Strong Potential of Biologics - Leading Players are AstraZeneca, Eli Lilly, Merck, Novo Nordisk & Sanofi - Research and Markets


Research and Markets has announced the addition of the "Global Diabetic Therapeutic Market 2017-2021" report to their offering.

The global diabetic therapeutic market to grow at a CAGR of 7.55% during the period 2017-2021.

The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.

The report covers the present scenario and the growth prospects of the global diabetic therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded drugs, generics, and biosimilars used for the treatment of diabetes. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period..

The report covers the market landscape and its growth prospects over te coming years. The report also includes a discussion of the key vendors operating in this market.

Market Dynamics

Market drivers


  • Change in patient preference
  • Focus on self-management of diabetes
  • The strong potential of biologics
  • Unmet medical needs and scope for DMDs

Market challenges

  • Complex storage conditions and distribution policies for insulin
  • Unpredictable outcomes on human due to lack of predictable animal models
  • Gap in nation-level diabetes management plans
  • Rising concerns in the scientific community

Market trends

  • Focus on oral insulin therapies
  • Growing technological integration fueling the market growth
  • Focus on regenerative medicines
  • Strong and diversified pipeline portfolio

Key vendors

  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Disease overview: Diabetes

Part 06: Pipeline portfolio

Part 07: Market landscape

Part 08: Overview of marketed products

Part 09: Market segmentation by type of disease

Part 10: Market segmentation by drug class

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

Part 19: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/rgft9k/global_diabetic


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy